
ROIV Stock Forecast & Price Target
ROIV Analyst Ratings
Bulls say
Roivant Sciences Ltd demonstrates a strong outlook due to the commercial potential of its drug candidates, particularly brepocitinib, which offers a significant therapeutic advancement in comparison to existing treatments for dermatomyositis (DM). The drug's convenient once-daily dosing provides a competitive edge over the current therapy, IVIg, which generates approximately $500 million in global sales but requires cumbersome infusion sessions. Additionally, brepocitinib's clinical results, including a notable mean total improvement score (TIS) of 46.5, underpin its efficacy and could enhance market confidence and investor interest in Roivant Sciences's portfolio.
Bears say
Roivant Sciences Ltd has experienced significant setbacks in its clinical development pipeline, including the failures of crucial assets such as IMVT and brepocitinib in various trials, which undermines investor confidence in its future growth prospects. The repeated failures highlight the risks associated with its reliance on a narrow range of developmental candidates, placing increased pressure on the success of VTAMA as its sole commercialized product. These factors raise concerns regarding the company's ability to achieve sustainable revenue generation, thereby contributing to a negative outlook on its stock performance.
This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.
ROIV Analyst Forecast & Price Prediction
Start investing in ROIV
Order type
Buy in
Order amount
Est. shares
0 shares